Hostname: page-component-745bb68f8f-lrblm Total loading time: 0 Render date: 2025-01-24T07:01:03.792Z Has data issue: false hasContentIssue false
  • English
  • Français

Medication Use in Patients Presenting to a Rural and Remote Memory Clinic

Published online by Cambridge University Press:  02 December 2014

Trevor A Steve ,
Andrew Kirk ,
Margaret Crossley ,
Debra Morgan ,
Carl D'Arcy ,
Jay Biem ,
Dorothy Forbes  and
Norma Stewart
Trevor A Steve
Affiliation:
University of Saskatchewan, Saskatoon, Saskatchewan
Andrew Kirk*
Affiliation:
University of Saskatchewan, Saskatoon, Saskatchewan
Margaret Crossley
Affiliation:
University of Saskatchewan, Saskatoon, Saskatchewan
Debra Morgan
Affiliation:
University of Saskatchewan, Saskatoon, Saskatchewan
Carl D'Arcy
Affiliation:
University of Saskatchewan, Saskatoon, Saskatchewan
Jay Biem
Affiliation:
McGill University, Montreal, Quebec
Dorothy Forbes
Affiliation:
University of Western Ontario, London, Ontario
Norma Stewart
Affiliation:
University of Saskatchewan, Saskatoon, Saskatchewan
*
Royal University Hospital, Dept of Medicine (Neurology), 103 Hospital Drive, Saskatoon, Saskatchewan, S7N 0W8. Canada.
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Peer Reviewed Letter
Information
Canadian Journal of Neurological Sciences , Volume 35 , Issue 5 , November 2008 , pp. 669 - 671
Copyright
Copyright © The Canadian Journal of Neurological 2008

References

1. Mesulam, MM. The cholinergic innervation of the human cerebral cortex. Prog Brain Res. 2004;145:67–78.CrossRefGoogle ScholarPubMed
2. Nathanson, NM. Regulation of muscarinic acetylcholine receptor expression and function. Prog Brain Res. 1996;109:166–8.Google ScholarPubMed
3. Everitt, BJ, Robbins, TW. Central cholinergic systems and Cognition, 1997. Annu Rev Psychol. 1997;48:649–84.CrossRefGoogle Scholar
4. Davies, P, Maloney, AJ. Selective loss of central cholinergic neurons in Alzheimer’s disease. Lancet. 1976;2:1403.Google Scholar
5. Bartus, RT, Dean, RL 3rd, Beer, B, Lippa, AS. The cholinergic hypothesis of geriatric memory dysfunction. Science. 1982;217:408–14.Google Scholar
6. Rogers, SL, Doody, RS, Mohs, R, Friedhoff, LT. Donepezil improves cognition and global function in alzheimer disease: a 15-week, double-blind, placebo-controlled study. Arch Intern Med. 1998;158:1021–31.Google Scholar
7. Rosler, M, Anand, R, Cicin-Sain, A, Gauthier, S, Agid, Y, Dal-Bianco, P, et al. Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomised controlled trial. Brit Med J. 1999;318:633–40.Google Scholar
8. Tariot, PN, Solomon, PR, Morris, JC, Kershaw, P, Lilienfeld, S, Ding, C, et al. A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology. 2000;54:2269–76.Google Scholar
9. Sunderland, T, Tariot, PN, Cohen, RM, Weingartner, H, Mueller, EA 3rd, Murphy, DL. Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls: a dose-response study. Arch Gen Psychiat. 1987;44:418–26.Google Scholar
10. Beers, MH. Explicit criteria for determining potentially inappropriate medication use by the elderly: an update. Arch Int Med. 1997;157:1531–6.Google Scholar
11. Fick, DM, Cooper, JW, Wade, WE, Waller, JL, Maclean, JR, Beers, MH. Updating the beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Int Med. 2003;163:2716–24.CrossRefGoogle ScholarPubMed
12. Lechevallier-Michel, N, Molimard, M, Dartigues, J, Fabrigoule, C, Fourrier-Reglat, A. Drugs with anticholinergic properties and cognitive performance in the elderly: results from the PAQUID Study. Brit J Pharmacol. 2005;59:143–51.Google Scholar
13. Moore, AR, O’Keefe, ST. Drug-induced cognitive impairment in the elderly. Drug Aging. 1999;15:15–28.CrossRefGoogle ScholarPubMed
14. Folstein, MF, Folstein, SE, McHugh, PR. "Mini-mental state". A practical method for grading cognitive state of patients for the clinician. J Psychiat Res. 1975;12:189–98.CrossRefGoogle ScholarPubMed
15. Verdoux, H, Lagnaoui, R, Begaud, B. Is benzodiazepine use a risk factor for cognitive decline and dementia? A literature review of epidemiological studies. Psychol Med. 2005;35:307–15.Google Scholar
16. Lagnaoui, R, Begaud, B, Moore, N, Chaslerie, A, Fourrier, A, Letenneur, L, et al. Benzodiazepine use and risk of dementia: a nested case-control study. J Clin Epidemiol. 2002;55:314–18.Google Scholar
17. Foy, A, O’Connell, D, Henry, D, Kelly, J, Cocking, S, Halliday, J. Benzodiazepine use as a cause of cognitive impairment in elderly hospital inpatients. J Gerontol. 1995;50:M99–106.CrossRefGoogle ScholarPubMed
18. Roe, CM, Anderson, MJ, Spivack, B. Use of Anticholinergic medications by older adults with dementia. J Am Ger Soc. 2002;50:836–42.Google Scholar
19. Carrahan, RM, Lund, BC, Perry, PJ, Chrischilles, EA. The concurrent use of anticholinergics and cholinesterase inhibitors: Rare event or common practice? J Am Ger Soc. 2004;52:2082–7.CrossRefGoogle Scholar
20. Fujishiro, J, Imanishi, T, Onozawa, K, Tsushima, M. Comparison of the anticholinergic effects of the serotonergic antidepressants, paroxetine, fluvoxamine, and clomipramine. Eur J Pharmacol. 2002;454:183–8.CrossRefGoogle ScholarPubMed
21. Han, L, McCusker, J, Cole, M, Abrahamowicz, M, Primeau, F, Elie, M. Use of medications with anticholinergic effect predicts clinical severity of delirium symptoms in older medical inpatients. Arch Int Med. 2001;161:1099–105.Google Scholar